Samsung Biologics launches tender offer for PolyPeptide at CHF 44.31 per share

• Samsung Biologics launched a tender offer to acquire PolyPeptide Group at CHF 44.31 per share.
• The deal follows a strategic review that positioned the combination as a route to scale and faster growth in peptide-based therapeutics manufacturing.
• The announcement coincided with preliminary first-half 2026 results showing accelerating growth and profitability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPeptide Group AG published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.